Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neoplasms, Plasma Cell 2Multiple Myeloma 2Prostatic Neoplasms 1Breast Neoplasms 1

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × samarium Sm-153 lexidronam × Clear all
NCT00602706 2011-05-16

Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Mayo Clinic

Phase 1/2 Completed
76 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00478075 2011-05-11

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡